Suraxavir Marboxil Tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Jiangxi Kerui Pharmaceutical Co., Ltd.
- Medicine type
- Chemical medicine
- Therapeutic area
- Infectious diseases
- Indications recorded in the public source
- Treatment of uncomplicated influenza A or B in previously healthy adults and adolescents aged 12 years and older, excluding patients at high risk of influenza-related complications. The prescribing information requires treatment to begin within 48 hours of symptom onset.
- Indication source and scope
- 2026-06-26
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Limited to treatment of uncomplicated influenza A or B in previously healthy adults and adolescents aged 12 years and older, excluding patients at high risk of influenza-related complications.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.qfyy.com.cn/uploads/upload/files/20261019/4a5369d6087c50d2fd5876a7585d9b23.pdf
Open the interactive record, public price references and discussions